• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
The iVAX Toolkit: An in silico platform for epitope discovery with applications to human and animal vaccine design

The iVAX Toolkit: An in silico platform for epitope discovery with applications to human and animal vaccine design

by Annie De Groot | Oct 23, 2019

EpiVax_ISV_iVAX_23Oct19
Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

by Annie De Groot | Aug 2, 2019

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models
Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

by Annie De Groot | May 15, 2019

EpiVax_TaspoglutidePoster_14May19
In Silico Screening and Immune-Engineering Techniques for “Stealth” Receptor Targets of Immunotherapeutic Antibodies

In Silico Screening and Immune-Engineering Techniques for “Stealth” Receptor Targets of Immunotherapeutic Antibodies

by Annie De Groot | Oct 5, 2018

EpiVax_CPI-Targets_04Oct18_forPrinting
Next Entries »

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.